Iceland Moss (Cetraria islandica)
What Is Iceland Moss?
Iceland Moss is catalogued in the Materia Medica under the binomial Cetraria islandica, a lichen of the Parmeliaceae family, native to the arctic and alpine heaths of the Northern Hemisphere. The material in circulation is lichen thallus. Most people search for it simply as Iceland Moss; suppliers, pharmacopoeias and interaction databases list it as Cetraria islandica, and matching the two is the first step in identifying what is actually in a product. In the hand it reads as dry bitter-earthy with a faint mushroom note — a practical marker of freshness and correct identification.
The written history of Iceland Moss begins with household and practitioner use — recipes, harvesting notes and cautions passed between regions — and only much later with laboratory description of what the lichen thallus contains. Beyond its practical use it carries cultural associations — lichen of the far north — endurance in barren ground.
Today most searches for Iceland Moss come from people reading about lung support, appetite and oral health, or checking how it sits alongside a medication they already take. The use most often documented in the literature is EMA-recognised traditional use for dry cough and oral mucosal irritation, followed by lichenan mucilage forms a protective film on inflamed mucosa.
How Does Iceland Moss Work?
Iceland Moss is not a single active substance. Its chemistry is a mixture, and the fractions that researchers isolate most often are Polysaccharides. Polysaccharides is the fraction most often standardised in extracts, associated in the literature with immunostimulant carbohydrate polymers.
Traditional practice described Iceland Moss in terms of taste, warmth and preparation rather than molecules — a working vocabulary that predicted which extractions were worth making long before any compound was isolated.
The research base is developing: there are human trials, though sample sizes and designs vary, and this profile cites 1 source. Reported findings centre on contains lichenan and isolichenan polysaccharides (up to 50%) plus fumarprotocetraric and usnic acids as the bitter principles. Where research exists, it examines EMA-recognised traditional use for dry cough and oral mucosal irritation, lichenan mucilage forms a protective film on inflamed mucosa and bitter principles stimulate appetite in convalescence. These are areas of study, not established outcomes, and results differ by preparation and dose.
How the plant is prepared changes what you actually get. Its constituents move readily into water and alcohol — so a preparation made in another medium will not carry the same fraction of the plant, which is why traditional recipes specify one over another.
The reason Iceland Moss is treated as its own entry rather than a substitute for a related plant is proportion: related species share several of these compound classes, but not in the same ratio or concentration.
Because these constituents are processed by the same pathways that handle many medicines, Iceland Moss is documented as interacting with hepatotoxic drugs and oral medications. That is a question of shared metabolism rather than of potency, and it is the main reason the plant is listed in interaction references at all.
Dose, plant part and growing conditions all shift the constituent profile, so two products carrying the name Iceland Moss can differ substantially; this is why reference entries specify lichen thallus and, where they exist, standardisation markers.